Eli Lilly's Once-Daily Weight Loss Pill Orforglipron Shows Significant Reduction in Heart Disease Risk
Eli Lilly says Phase 3 Foundayo (Orforglipron) data show reduced cardiovascular and type 2 diabetes risks in adults with obesity.
Stocks · News reference
Novo Announces Wegovy Liver Fat Reductions To Normal Levels In 9 Out Of 10 Adults With Obesity And Excess Liver Fat
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Foghorn Therapeutics Pivots Pipeline after Ending Eli Lilly Deal
Foghorn Therapeutics stock drops as Eli Lilly ends partnership, prompting a 40% workforce cut to extend cash runway into 2029 while pivoting pipeline.
Foghorn Therapeutic Announces That The Company And Lilly Will Not Advance The FHD-909 Program Into The Clinical Development Expansion Phase
Over 88% Of Wegovy Trial Participants Achieve Normal Liver Fat Levels, Novo Reports
Novo Nordisk's Wegovy significantly reduced liver fat in adults with obesity in a recent post hoc analysis, potentially lowering MASH risk.
NVO's Ozempic Outshines LLY's Mounjaro in Lowering Cardiovascular Risk
Novo's COMPETE SWITCH CV study found that patients who escalated their Ozempic dose to 2 mg had a 6% lower observed risk of major adverse cardiovascular events (MACE) compared to those who switched to Eli Lilly's Mounjaro. However, the study shows association rather than causation and did not evaluate safety outcomes.
Novo Nordisk Says Next-Gen Obesity Drug Reduces Food Noise, Drives Weight Loss
Novo Nordisk presents data showing CagriSema reduces cravings and weight, while real-world patients switching to oral semaglutide also lost weight.